Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
7 evidence topics · 7 sources
Launch-HTN: 50 mg once daily, with escalation to 100 mg at week 6 in one group
“participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 270 participants randomized to 50 mg of lorundrostat once daily, 92 (34.1%) were escalated to the 100-mg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Advance-HTN: 50 mg once daily, or 50 mg increased to 100 mg after 4 weeks
“participants with an average 24-hour ambulatory blood pressure of 130/80 mm Hg or higher were assigned to receive placebo, lorundrostat at a stable dose of 50 mg daily (the stable-dose group), or lorundrostat at a starting dose of 50 mg daily, with an increase to 100 mg daily if systolic blood pressure was 130 mm Hg or higher after 4 weeks (the dose-adjustment group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Target-HTN: dose-ranging from 12.5 mg once daily to 100 mg once daily
“Cohort 1 participants were randomly assigned in a 1:1:1:1:1:1 ratio to placebo or 1 of 5 lorundrostat doses (12.5 mg, 50 mg, or 100 mg once daily or 12.5 mg or 25 mg twice daily).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transform-HTN: 50 mg once daily, or 25 mg after a dose reduction
Explore-CKD: 25 mg once daily
Doses evaluated in healthy participants
“The dosing cohorts were 5, 10, 20, 50, 100, 200, 400, and 800 mg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The final dose levels of lorundrostat for part 2 were 40, 120, and 360 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proposed labeled dose
No evidence found.